ESR1 and breast carcinoma: Our data show, for the first time to our knowledge, that acquisition of deregulated miRNA expression represents an alternative trick used by ER+ AI-resistant breast cancer cells to activate this crucial survival pathway and thus escape from AI endocrine therapy.